(-)Clausenamide 

(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD)^[1][2][3].

(-)Clausenamide (10 and 100 μM) reverses the overload in [Ca²⁺]_i level stimulated by Aβ_25-35, and reduces Aβ-mediated cell apoptosis in PC12 cells^[3].
(-)Clausenamide (10 and 100 μM) inhibits the phosphorylation of p38 MAPK, down-regulates the expression of P53 and cleaved Caspase-3 and the ratio of Bax/Bcl-2, in Aβ_25-35-treated PC12 cells^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

297.35

C₁₈H₁₉NO₃

201529-58-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chu S, Liu S, Duan W, et al. The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect. Pharmacol Ther. 2016;162:179-187.  [Content Brief]

  [2]. Chu SF, Zhang JT. Recent advances in the study of (-)clausenamide: chemistry, biological activities and mechanism of action. Acta Pharm Sin B. 2014;4(6):417-423.  [Content Brief]

  [3]. Hu JF, et al. Protective effect of (-)clausenamide against Abeta-induced neurotoxicity in differentiated PC12 cells. Neurosci Lett. 2010 Oct 8;483(1):78-82.  [Content Brief]